ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
6,002.00
1.09%
Dow Jones
43,522.46
0.86%
US Dollar vs MXN
20.78498
-0.25%
Brent Oil
80.015
-0.62%
Bitcoin
105,397.92
5.39%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Larimar Therapeutics Inc (LRMR) Cotización

Larimar Therapeutics Inc

Larimar Therapeutics Inc (LRMR)

NASDAQ
3.255
0.005
( 0.15% )
Actualizado: 13:57:11
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
3.255
Postura de Compra
3.25
Postura de Venta
3.26
Volume Operado de la Acción
300,547
3.21 Rango del Día 3.3888
3.01 Rango de 52 semanas 13.68
Capitalización de Mercado [m]
207.691M
Precio Anterior
3.25
Precio de Apertura
3.32
Hora
100
@
3.2546
(average)
Última hora de negociación
13:59:47
Volumen financiero
US$ 982,675
Precio Promedio Ponderado
3.2696
Volumen promedio (3 m)
825,457
Acciones en circulación
63,806,628
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.71
Beneficio por acción (BPA)
-0.58
turnover
-
Beneficio neto
-36.95M

Acerca de Larimar Therapeutics Inc

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
larimartx.com
Sede
Wilmington, Delaware, USA
Fundado
-
Larimar Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LRMR. The last closing price for Larimar Therapeutics was US$3.25. Over the last year, Larimar Therapeutics shares have traded in a share price range of US$ 3.01 to US$ 13.68.

Larimar Therapeutics currently has 63,806,628 shares in issue. The market capitalisation of Larimar Therapeutics is US$207.37 million. Larimar Therapeutics has a price to earnings ratio (PE ratio) of -1.71.

LRMR Últimas noticias

Más noticias

Form 8-K - Current report

10 Enero 2025
Edgar (US Regulatory)

Form 8-K - Current report

16 Diciembre 2024
Edgar (US Regulatory)

Form 8-K - Current report

18 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Noviembre 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Noviembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

30 Octubre 2024
Edgar (US Regulatory)

Form 8-K - Current report

30 Octubre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 Agosto 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 Agosto 2024
Edgar (US Regulatory)

Form 8-K - Current report

10 Junio 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.495-13.23.753.753.214334513.4449574CS
4-0.695-17.59493670893.954.273.216067603.85205976CS
12-4.745-59.312589.53.018254575.82230853CS
26-7.035-68.367346938810.2910.373.016741846.54552935CS
52-0.855-20.8029197084.1113.683.016224967.65483703CS
156-5.755-63.87347391799.0113.681.533350566.21442405CS
260-8.745-72.8751225.871.532434616.95454113CS

LRMR - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Larimar Therapeutics?
El precio actual de las acciones de Larimar Therapeutics es US$ 3.255
¿Cuántas acciones de Larimar Therapeutics están en circulación?
Larimar Therapeutics tiene 63,806,628 acciones en circulación
¿Cuál es la capitalización de mercado de Larimar Therapeutics?
La capitalización de mercado de Larimar Therapeutics es USD 207.37M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Larimar Therapeutics?
Larimar Therapeutics ha negociado en un rango de US$ 3.01 a US$ 13.68 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Larimar Therapeutics?
El ratio precio/beneficio de Larimar Therapeutics es -1.71
¿Cuál es la moneda de reporte de Larimar Therapeutics?
Larimar Therapeutics presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Larimar Therapeutics?
El último beneficio anual de Larimar Therapeutics es USD -36.95M
¿Cuál es la dirección registrada de Larimar Therapeutics?
La dirección registrada de Larimar Therapeutics es CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Larimar Therapeutics?
La dirección del sitio web de Larimar Therapeutics es larimartx.com
¿En qué sector industrial opera Larimar Therapeutics?
Larimar Therapeutics opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BTCTBTC Digital Ltd
US$ 9.12
(91.60%)
46.34M
CRKNCrown Electrokinetics Corporation
US$ 0.1383
(73.53%)
646.49M
BDMDBaird Medical Investment Holdings Ltd
US$ 9.00
(66.05%)
17.48M
NUKKNukkleus Inc
US$ 31.49
(53.39%)
17.59M
BTCSBTCS Inc
US$ 4.0994
(52.96%)
4.86M
SHOTWSafety Shot Inc
US$ 0.15
(-33.33%)
5.31k
PMAXPowell Max Ltd
US$ 0.639
(-22.99%)
3.5M
LGCBLinkage Global Inc
US$ 0.2854
(-22.86%)
788.31k
AENTAlliance Entertainment Holding Corporation
US$ 4.82
(-18.86%)
162.79k
BLRXBioLineRx Ltd
US$ 0.0994
(-18.46%)
24.52M
CRKNCrown Electrokinetics Corporation
US$ 0.14
(75.66%)
646.78M
GCTKGlucoTrack Inc
US$ 0.0891
(20.73%)
447.02M
RIMEAlgorhythm Holdings Inc
US$ 0.043
(1.65%)
297.57M
TGLTreasure Global Inc
US$ 0.2527
(17.92%)
258.89M
NVDANVIDIA Corporation
US$ 137.81
(3.17%)
145.42M

LRMR Discussion

Ver más
tw0122 tw0122 6 meses hace
LRMR above $9 momentarily
👍️0
Monksdream Monksdream 9 meses hace
LRMR under $10

👍️0
Monksdream Monksdream 10 meses hace
LRMR under $10
👍️0
Monksdream Monksdream 11 meses hace
LRMR new 52 week high
👍️0
Monksdream Monksdream 11 meses hace
LRMR new 52=week high
👍️0
AJ Freely AJ Freely 1 año hace
$LRMR - Announced that the FDA has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601
👆Up 8% Pre-Market/ Current Price $3,40
👍️0
magacrew2020 magacrew2020 2 años hace
could probably get through approval on just 25 mg if they are going to approve reta
👍️0
subslover subslover 2 años hace
The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.
👍️0
JJJ54 JJJ54 3 años hace
I voted NO on the 2022 Annual Meeting Vote. I recommend you do the same.
👍️0
DarkPool DarkPool 3 años hace
Interesting.
👍️0
oxnous oxnous 4 años hace
Waking up . But volume should be higher.
👍️0
DewDiligence DewDiligence 4 años hace
LRMR 2Q20 results—6/30/20 cash=$113.7M:

https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html

No CC.
👍️0
casenumber casenumber 5 años hace
Large chunks are being gobbled
Whales are lurking around?
👍️0
subslover subslover 5 años hace
The company they are merging with looks pretty darn impressive
https://chondrialtherapeutics.com/
👍️0
casenumber casenumber 5 años hace
Volume!
👍️0
ClayTrader ClayTrader 5 años hace
* * $ZFGN Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 años hace
* * $ZFGN Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 5 años hace
News: $ZFGN Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

Got this from ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?
👍️0
Fat Thor Fat Thor 5 años hace
Like I said at .67 cents
👍️0
ClayTrader ClayTrader 5 años hace
* * $ZFGN Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
casenumber casenumber 5 años hace
Wow...guess they will satisfy the 1dollar minimum nasd requirement with out rs.....
This will be huge when ticker change and merger consummated next month!

Scrap the notice of delisting boys.....

82M cash and 30M OS....sounds fun!
👍️0
ClayTrader ClayTrader 5 años hace
* * $ZFGN Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
casenumber casenumber 5 años hace
Over a buck soon when ticker change completed....
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
exactly is great
👍️0
Fat Thor Fat Thor 5 años hace
Probably 3-9 months away still - appears to be a massive over correction and tax loss selling on the merger news. Just a short target at the moment. They will run this in Q1 pre-split to get a much more favorable ratio IMO. Let's see what happens. Lots of cash on hand here at very low burn rate per Q.

The transaction is expected to close in the first half of 2020, subject to approvals by stockholders of each company and other customary closing conditions.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
R/Split coming per 8k today
👍️0
Fat Thor Fat Thor 5 años hace
December discounts. With 85 million in cash, a merger, and priced at 67 cents there's no way this doesn't run soon. 35 million O/S.
👍️0
casenumber casenumber 5 años hace
Ticker change coming...Shorts will get burn if they will not cover or do damage control.
ZFGN has 82M dollars in cash!

The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.
👍️0
casenumber casenumber 5 años hace
Shorts covering.. they have to before it gets out of control once the merger is official...
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
10 day MA live chart huge oversold,safe here now,will recover nice
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
bought 3k at 6391
👍️0
Fat Thor Fat Thor 5 años hace
Just saw a bunch come through on tape that were vastly different but didn't indicate "out of sequence"...they were either out of sequence or it was a messed up market order. Just odd. This one is clearly under short attack. Volume could squeeze it near term.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
ZFGN~~Balance Sheet
Total Cash (mrq) 82.01M
Total Cash Per Share (mrq) 2.19
Total Debt (mrq) 24.35M
Total Debt/Equity (mrq) 40.67
Current Ratio (mrq) 5.11
Book Value Per Share (mrq) 1.60
https://finance.yahoo.com/quote/ZFGN/key-statistics?p=ZFGN



👍️0
alchemytrader alchemytrader 5 años hace
not really. that would mean its been up and down, up and down. this is nothing but down..
👍️0
Fat Thor Fat Thor 5 años hace
...this price action is ALL over the place. Crazy.
👍️0
alchemytrader alchemytrader 5 años hace
man i hope so. just want out even now
👍️0
BoilerRoom BoilerRoom 5 años hace
$ZFGN in at .70
👍️0
BoilerRoom BoilerRoom 5 años hace
Short this
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
will recover but sucks,waste of time
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m.,
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
Conference Call Information
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m., Eastern Time, to discuss the merger as well as other forward-looking information. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 5688136. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 11:30 a.m. ET on December 18, 2019 through December 25, 2019 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 5688136.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
dont think so
👍️0
Widowsson32 Widowsson32 5 años hace
This is done no benefit to this company but ONTX will make you very rich
👍️0
alchemytrader alchemytrader 5 años hace
institutions selling off?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
the news is great,why?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
fffffffffffffffffff MMS
👍️0
alchemytrader alchemytrader 5 años hace
i guess were screwed
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
f MMs
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
.79 f
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 años hace
what the heck is going on here?
👍️0

Su Consulta Reciente

NASDAQ
LRMR
Larimar Therapeutics
ASX
PCX
Pengana Global Private C...
NYSE
AFTR.U
AfterNext HealthTech Acq...
BIT
NSCIT9091868
ING Groep
BIT
NSCIT0554740
Italy
BIT
NSCIT5496772
Italy
BIT
NSCIT2107448
IBRD
BIT
WNUS26
Nusco
BIT
F34703
Vontobel Financial Produ...
BIT
F34599
Vontobel Financial Produ...
BIT
UC1C56
Unicredit Bank
NASDAQ
FFBC
First Financial Bancorp
BIT
NSCIT2749785
International Bank for R...
BIT
I09184
Intesa Sanpaolo
BIT
UC72NE
Unicredit Bank
BIT
I09303
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados